LIVE
ALGN
Align Technology, Inc. · Healthcare - Medical Devices
$182.08
+17.35% this month
VERSUS
⟷
COMPARE
XRAY
Dentsply Sirona, Inc. · Healthcare - Dental Equipment & Supplies
$10.33
+6.06% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
ALGN
3
XRAY
2
Comparison scoreboard
ALGN LEADS 3/5AI Score
ALGN ✓38.0
XRAY 24.3
1Y Return
ALGN ✓+3.95%
XRAY -32.92%
Fwd P/E
ALGN 14.13
XRAY ✓6.53
Target Up.
ALGN +19.58%
XRAY ✓+32.80%
Op. Margin
ALGN ✓16.59%
XRAY 3.41%
Metrics last refreshed: 6/20/2026
Quick take
ALGN vs XRAY Stock Comparison: AI Score, Valuation, Performance and Upside
ALGN (Align Technology) and XRAY (Dentsply Sirona) are both major dental companies with orthodontic offerings — Align Technology is the pure-play clear aligner leader with the Invisalign consumer brand and iTero digital scanning ecosystem, while Dentsply Sirona is a broad-based dental products company covering the full dental office with traditional orthodontics, digital equipment, and consumables alongside its SureSmile clear aligner. Align is the focused disruptor; Dentsply is the diversified incumbent.
ALGN vs XRAY is clear aligner category creator defending premium brand (Align Technology's Invisalign ecosystem with consumer brand recognition and digital scanning workflow integration) versus diversified dental incumbent competing across all dental modalities (Dentsply's broad dental portfolio including direct aligner competition through SureSmile and full-practice equipment solutions) — focused orthodontic innovator versus diversified dental equipment and supplies leader.
Live analysis · updated 6/20/2026
ALGN holds the edge across 3 of 5 key metrics in this comparison. ALGN has delivered stronger 1-year price return (+3.95% vs -32.92%), though XRAY trades at the lower forward P/E (6.53x vs 14.13x). ALGN leads on both revenue growth (6.20%) and operating margin (16.59%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for XRAY (+32.80%) than for ALGN (+19.58%).
Normalized 1Y performance
ALGN
XRAY
Recent returns
ALGN
XRAY
Analyst price targets & sentiment
ALGN · 15 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$150.54
analyst high$275.00
analyst mean$209.07
current price$182.08
+19.6% upside to analyst mean
XRAY · 14 analysts
STRONG BUYHOLDSTRONG SELL
Hold (2.6/5.0)
Price target range
analyst high$25.00
analyst mean$13.40
current price$10.33
+32.8% upside to analyst mean
Who should consider this stock?
ALGN may suit investors who:
- →Want the clear aligner market leader with the only consumer-recognized brand in orthodontics — Invisalign's brand pull creates demand that flows through to orthodontist offices, maintaining Align's market position
- →Value the iTero digital scanner installed base as creating a digital workflow moat that keeps orthodontic practices integrated with Align's treatment planning ecosystem
- →See continued global clear aligner market penetration growth (especially in teen orthodontics and emerging markets) as a long-term organic growth driver as Invisalign awareness expands
XRAY may suit investors who:
- →Want diversified dental products exposure across equipment, consumables, and orthodontics through a single broad dental company with global distributor relationships
- →Value Dentsply's portfolio breadth as providing revenue resilience across dental equipment upgrade cycles and consumable reorder patterns from a large installed practice base
- →See Dentsply's current challenges (accounting restatements, management turnover, market share losses) as potentially creating a turnaround opportunity if operational execution improves
Performance & AI score
| Metric | ALGN | XRAY |
|---|---|---|
| AI score | 38.0 | 24.3 |
| AI rank | #1325 | #3167 |
| Latest close | $182.08 | $10.33 |
| 1M return | +17.35% | +6.06% |
| 6M return | +13.39% | -9.62% |
| 1Y return | +3.95% | -32.92% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | ALGN | XRAY |
|---|---|---|
| 1Y ago | $10.11K (+1.1%) started 2025-06-18 | $6.71K (-32.9%) started 2025-06-18 |
| 5Y ago | $2.98K (-70.2%) started 2021-06-21 | $1.64K (-83.6%) started 2021-06-18 |
| 10Y ago | $22.85K (+128.5%) started 2016-06-20 | $1.63K (-83.7%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | ALGN | XRAY |
|---|---|---|
| Market cap | $12.52B | $2.02B |
| Trailing P/E | 29.43 | N/A |
| Forward P/E | 14.13 | 6.53 |
| Price/Sales | 3.29 | 0.85 |
| EV/Revenue | 2.83 | 1.14 |
| Analyst target | $209.07 | $13.40 |
| Target upside | +19.58% | +32.80% |
Growth, profitability & risk
| Metric | ALGN | XRAY |
|---|---|---|
| Revenue growth | 6.20% | 0.10% |
| Earnings growth | 23.90% | 15.20% |
| EPS growth | +23.90% | +15.20% |
| FCF margin | +13.16% | +3.52% |
| Operating margin | 16.59% | 3.41% |
| Profit margin | 10.50% | -17.06% |
| ROIC proxy | 10.82% | -37.67% |
| Return on equity | 10.82% | -37.67% |
| Dividend yield | N/A | 5.04% |
| Beta | 1.67 | 0.91 |
| Debt/equity | 2.80 | 177.79 |
| Current ratio | 1.39 | 1.53 |
| Quick ratio | 1.17 | 0.67 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
ALGN max drawdown39.73%
XRAY max drawdown42.79%
ALGN max wkly drop36.19%
XRAY max wkly drop14.10%
5Y risk snapshot
ALGN max drawdown82.89%
XRAY max drawdown85.55%
ALGN max wkly drop36.19%
XRAY max wkly drop27.65%
10Y risk snapshot
ALGN max drawdown82.89%
XRAY max drawdown86.05%
ALGN max wkly drop36.19%
XRAY max wkly drop27.65%
Performance metrics by period
| Period | Metric | ALGN | XRAY |
|---|---|---|---|
| 1Y | Growth | +1.15% | -32.92% |
| CAGR | +1.15% | -32.94% | |
| Sharpe ratio | 0.24 | -0.79 | |
| Max drawdown | 39.73% | 42.79% | |
| Max daily drop | 36.63% | 12.68% | |
| Max wkly drop | 36.19% | 14.10% | |
| 5Y | Growth | -70.23% | -83.65% |
| CAGR | -21.55% | -30.39% | |
| Sharpe ratio | -0.32 | -0.90 | |
| Max drawdown | 82.89% | 85.55% | |
| Max daily drop | 36.63% | 28.02% | |
| Max wkly drop | 36.19% | 27.65% | |
| 10Y | Growth | +128.54% | -83.69% |
| CAGR | +8.62% | -16.59% | |
| Sharpe ratio | 0.33 | -0.48 | |
| Max drawdown | 82.89% | 86.05% | |
| Max daily drop | 36.63% | 28.02% | |
| Max wkly drop | 36.19% | 27.65% |
Business comparison
| Category | ALGN | XRAY |
|---|---|---|
| Company | Align Technology, Inc. | Dentsply Sirona, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Instruments & Supplies |
| Core business | Align Technology is the creator and market leader in clear aligner orthodontics — the Invisalign system uses a series of custom-fabricated clear plastic aligners to straighten teeth without traditional metal braces. Align's iTero digital scanners allow orthodontists and dentists to digitally scan patients' teeth for Invisalign treatment planning. Align serves orthodontists and general practice dentists who prescribe Invisalign to patients globally. | Dentsply Sirona is the world's largest dental products company — providing a comprehensive range of dental equipment (chairs, imaging systems, X-ray equipment, CAD/CAM milling), consumables (restorative materials, endodontic files, implants, orthodontic products including traditional braces and Suresmile clear aligners), and digital dentistry platforms. Dentsply serves dentists, dental specialists, and dental labs globally through a broad distributor network. |
| Investor focus | Investors track Align's case volume (number of Invisalign cases shipped to doctors), average selling price trends, channel expansion into general practice dentistry (GPs), teen segment penetration (historically lower than adult), China and emerging market growth, and competition from in-house clear aligner brands (3M Clarity, Ormco Spark) and direct-to-consumer clear aligner companies. | Investors track Dentsply's equipment versus consumable revenue, digital dentistry platform adoption (SureSmile clear aligners, Primescan intraoral scanners), organic revenue growth ex-acquisitions, operating margin improvement, and the competitive landscape in dental equipment and orthodontics where Align Technology and 3Shape compete. |
ALGN strengths
- →Invisalign brand recognition and patient demand — Invisalign is a consumer-recognized brand; many patients request Invisalign by name when seeking orthodontic treatment, creating pull-through demand for doctors who become Invisalign certified
- →Digital workflow integration through iTero scanners — Align's iTero intraoral scanners are placed in orthodontic offices and create a digital scanning workflow that feeds naturally into Invisalign treatment planning, increasing practice stickiness
- →Global orthodontic market expansion — clear aligner penetration is still relatively low versus traditional braces in most markets; as Invisalign awareness grows globally and more orthodontists become certified, the addressable market continues expanding
XRAY strengths
- →Broadest dental product portfolio addressing entire dental office workflow — Dentsply's products span from dental chairs and imaging to restorative materials, implants, and orthodontics; this one-stop-shop positioning helps with dental distributor and large DSO (Dental Service Organization) relationships
- →SureSmile clear aligner competitive product — Dentsply's SureSmile system offers a competitive clear aligner alternative to Invisalign at potentially lower cost for dental practices, capturing some of the orthodontic digitization opportunity
- →Global consumables base provides recurring revenue resilience — Dentsply's large installed base of dental practices using its restorative materials, endodontic products, and imaging systems generates recurring consumable purchases regardless of equipment upgrade cycles
Risks to watch — ALGN
- →Competition from Ormco Spark, 3M Clarity, and lower-cost aligner brands — multiple dental companies have launched competing clear aligners; Align must maintain its brand premium and clinical outcomes differentiation to justify ASP premiums
- →DTC clear aligner disruption — direct-to-consumer aligner companies (SmileDirectClub, Byte, Candid) attempted to disrupt by eliminating in-office visits; while SmileDirectClub went bankrupt in 2023, the DTC channel demonstrated consumer demand for convenience and price that incumbents must address
- →Economic sensitivity of elective dental procedures — Invisalign treatment is an elective procedure costing $3,000-8,000; when consumers face economic stress, orthodontic starts can decline as patients defer discretionary treatments
Risks to watch — XRAY
- →Market share losses in digital dentistry to Align Technology, 3Shape, and Carestream — Dentsply faces strong competition in digital scanning and clear aligners from more focused competitors
- →Accounting irregularities and restatements — Dentsply has faced internal investigation, executive departures, and earnings restatements that have damaged investor trust and management credibility
- →DSO consolidation channel pressure — large Dental Service Organizations buying groups have significant purchasing power; their consolidation and preference negotiations can pressure Dentsply's selling prices
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
More comparisons
Browse all 1,000 comparisons →